Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1309-1314

  Cantoni, Nathan ^a   Hirsch, Hans H ^a,b   Khanna, Nina ^a,b   Gerull, Sabine ^a   Buser, Andreas ^a   Bucher, Christoph ^a   Halter, Jörg ^a   Heim, Dominik ^a   Tichelli, André ^a   Gratwohl, Alois ^a   Stern, Martin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Acute GVHD; Allogeneic HSCT; CMV; Complications

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD ASSESSMENT; HUMAN; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; RETROSPECTIVE STUDY; VIRUS PNEUMONIA; VIRUS REPLICATION; WHOLE BODY RADIATION;

EID: 77955508946     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.020     Document Type: Article

References (29)

1. Appelbaum F.R. Hematopoietic-cell transplantation at 50. N Engl J Med 2007, 357:1472-1475.
2. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
3. Miller W., Flynn P., McCullough J., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986, 67:1162-1167.
4. Martino R., Rovira M., Carreras E., et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001, 86:1075-1086.
5. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
6. Appleton A.L., Sviland L. Pathogenesis of GVHD: role of herpes viruses. Bone Marrow Transplant 1993, 11:349-355.
7. Wang L.R., Dong L.J., Zhang M.J., Lu D.P. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 42:673-677.
8. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
9. Deeg H.J., Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med 1984, 35:11-24.
10. Broers A.E., van Der Holt R., van Esser J.W., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000, 95:2240-2245.
11. Bostrom L., Ringden O., Sundberg B., Linde A., Tollemar J., Nilsson B. Pretransplant herpesvirus serology and acute graft-versus-host disease. Transplantation 1988, 46:548-552.
12. Bostrom L., Ringden O., Gratama J.W., Jacobsen N., Zwaan F., Nilsson B. The impact of pretransplant herpesvirus serology on acute and chronic graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Transplant Proc 1990, 22:206-207.
13. Lonnqvist B., Ringden O., Wahren B., Gahrton G., Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984, 38:465-468.
14. Jacobsen N., Andersen H.K., Skinhoj P., et al. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scand J Haematol 1986, 36:499-506.
15. Gratama J.W., Fibbe W.E., Naipal A.M., et al. Cytomegalovirus immunity and T lymphocytes in bone marrow donors and acute graft-versus-host disease. Bone Marrow Transplant 1986, 1:141-146.
16. Gratama J.W., Zwaan F.E., Stijnen T., et al. Herpes-virus immunity and acute graft-versus-host disease. Lancet 1987, 1:471-474.
17. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
18. Ringden O., Schaffer M., Le Blanc K., et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. Biol Blood Marrow Transplant 2004, 10:128-134.
19. Larsson K., Aschan J., Remberger M., Ringden O., Winiarski J., Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004, 77:526-531.
20. Grefte A., van der Giessen M., van Son W., The T.H. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993, 167:270-277.
21. Ringden O., Pihlstedt P., Markling L., et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991, 7:221-226.
22. Carlens S., Ringden O., Remberger M., et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998, 22:755-761.
23. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
24. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.
25. Meyers J.D., Reed E.C., Shepp D.H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988, 318:70-75.
26. Winston D.J., Ho W.G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993, 118:179-184.
27. Griffiths P., Whitley R., Snydman D.R., Singh N., Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008, 15:4-12.
28. Trofe J., Pote L., Wade E., Blumberg E., Bloom R.D. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother 2008, 42:1447-1457.
29. Winston D.J., Young J.A., Pullarkat V., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.